Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) started the day on Wednesday, with a price decrease of -6.21% at $12.53, before settling in for the price of $13.36 at the close. Taking a more long-term approach, CNTA posted a 52-week range of $7.90-$19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its Annual Earning per share during the time was -210.04%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 37.42%. This publicly-traded company’s shares outstanding now amounts to $133.55 million, simultaneously with a float of $84.83 million. The organization now has a market capitalization sitting at $1.67 billion. At the time of writing, stock’s 50-day Moving Average stood at $12.89, while the 200-day Moving Average is $15.31.
Centessa Pharmaceuticals plc ADR (CNTA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Centessa Pharmaceuticals plc ADR’s current insider ownership accounts for 36.48%, in contrast to 57.67% institutional ownership. According to the most recent insider trade that took place on May 27 ’25, this organization’s Chief Business Officer sold 10,000 shares at the rate of 12.82, making the entire transaction reach 128,225 in total value, affecting insider ownership by 122,279.
Centessa Pharmaceuticals plc ADR (CNTA) Earnings and Revenue Records
Centessa Pharmaceuticals plc ADR’s EPS increase for this current 12-month fiscal period is 37.42% and is forecasted to reach -1.48 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 8.99% through the next 5 years, which can be compared against the -210.04% growth it accomplished over the previous five years trading on the market.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Let’s observe the current performance indicators for Centessa Pharmaceuticals plc ADR (CNTA). It’s Quick Ratio in the last reported quarter now stands at 14.37. The Stock has managed to achieve an average true range (ATR) of 0.77. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 111.12.
In the same vein, CNTA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.80, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -1.48 at the market close of one year from today.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
If we take a close look at the recent performances of Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA), its last 5-days Average volume was 0.7 million that shows plunge from its year to date volume of 0.87 million. During the previous 9 days, stock’s Stochastic %D was recorded 57.23% While, its Average True Range was 0.73.
Raw Stochastic average of Centessa Pharmaceuticals plc ADR (CNTA) in the period of the previous 100 days is set at 30.87%, which indicates a major fall in contrast to 31.05% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.55% that was lower than 62.95% volatility it exhibited in the past 100-days period.
